New Medical Innovations

The healthyher.life team supports a holistic approach to managing women’s hormonal healthcare. Our goal is to help our members be well-informed about their hormonal health, by providing them with evidence-based integrated health information that includes the current standard of medical care advised by qualified physicians, clinical insights from licensed allied health professionals (naturopathic doctors, nurse-practitioners, nutritionists, psychotherapists) and new health innovations that will be soon coming to market. Always consult with your doctor regarding your medical condition, diagnosis, treatment, or to seek personalized medical advice.
Related Readings: Endometriosis
Coming soon
Coming soon
Virtual reality digital solution offers free alternative to help women with endometriosis manage their pain
Source: Journal of International Medical Research
June 28, 2023
Management of chronic pelvic pain for individuals with endometriosis is complex and often requires the long-term use of prescription drugs (e.g., opioids), making drug-free alternatives for pain management highly sought after. A randomized controlled clinical trial conducted by the Franco European Multidisciplinary Endometriosis Institute (France) evaluated the efficacy and safety of using virtual reality (VR) in an immersive digital therapeutic (DTx) treatment for women with endometriosis suffering from moderate-to-severe pelvic pain. The study found that 20 minute VR sessions led to reduced medication intake, presenting a drug free approach to managing chronic pain at home and advancing the use of VR in pain management.

Coming soon
Coming soon
A new potential non-invasive biomarker for endometriosis
Source: Journal of International Medical Research
December 2023
A study published in the Journal of International Medical Research found that leukorrhea-exosomes – small vesicles that store biological information derived from vaginal discharge – have shown promising potential as non-invasive biomarkers for diagnosing endometriosis. The research article sheds light on the importance of developing valuable non-invasive diagnostic tools as an alternative to invasive laparoscopic surgery for improved early detection of endometriosis.

Fezolinetant And Elizanetant: What Should You Know About These New Non-Hormonal Therapies For Menopause
By Susan Johnson
Reviewed by Rina Carlini, PhD
October 30, 2024

For decades, hormone replacement therapy (HRT) has been the standard for treating menopausal symptoms, especially vasomotor symptoms (VMS) like hot flashes and night sweats, which affect nearly 80% of women during menopause.[1] However, HRT isn’t suitable for everyone. Women with a history of breast cancer and blood clots are not typically prescribed hormonal therapies since they can increase the risk of recurrence.
Until recently, there were only a few non-hormonal treatment options available for treating the disruptive symptoms of menopause, and they are mostly naturopathic treatments. However, that is changing with the development of new non-hormonal pharmaceutical drugs like fezolinetant (available under the commercial name VEOZAH™) and elinzanetant–the latest therapies and the first significant advances in more than two generations for managing vasomotor symptoms (VMS) associated with perimenopause and menopause.
What Is Fezolinetant And Elinzanetant?
Fezolinetant (developed by Astellas Pharma) and elinzanetant (developed by Bayer) are both non-hormonal oral medications that are indicated to specifically treat the VMS associated with menopause. In May 2023, fezolinetant made history as the first of its kind to be approved by the US Food and Drug Administration (FDA) for treating severe VMS.[2] Although Bayer’s elinzanetant hasn’t been commercialized yet, it was recently submitted for FDA approval in August 2024.[3]
How Do These Drugs Work?
Fezolinetant and elizanetant are not synthetic hormone drugs like conventional HRT drugs. Instead, these are a new class of drugs that act on the neural activity that causes flushing and sweating spells in women who are experiencing the perimenopause transition.
Recently, researchers identified a new pathway in the brain that could potentially be responsible for the VMS experienced by menopausal women. This pathway involves the kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which contain neurokinin 3 (NK3) receptors on their surface. When estrogen binds to the NK3 receptors, it inhibits the KNDy neurons that cause VMS. On the other hand, neurokinin B (NKB) stimulates the receptors and signals the induction of hot flashes.[4]
Before menopause, a balance exists between estrogen and NKB in the body. This balance helps women regulate their body temperature based on their surroundings. However, during menopause, when estrogen levels drop significantly, the balance gets disrupted. More NKB binds to the NK3 receptors, causing increased KNDy neuronal activity, which in the long term leads to the hypertrophy (or enlargement) of KNDy neurons. This affects the woman’s ability to regulate core body temperature and triggers hot flashes. [4]
Fezolinetant is a selective NK3 receptor antagonist. It binds to NK3 receptors, making them unavailable for NKB to bind to, which in turn blocks neuronal activity and supports thermoregulation, thereby reducing the frequency and severity of menopausal VSM. [5]
Elizanetant works similar to fezolinetant. However, it is a dual receptor antagonist drug that targets two receptors in the brain: NK3, which regulates body temperature, and NK1, which affects mood and sleep. [6]
"Oftentimes, the focus on a lot of these drugs is hot flashes, hot flashes, hot flashes, but we know hot flashes do not occur in isolation,” said Chrisandra Shufelt, MD, professor and chair of general internal medicine and associate director of the Women's Health Research Center at Mayo Clinic. “Elinzanetant is an interesting compound because it actually works on sleep, and that was critical because sleep disturbance precedes many other menopausal symptoms,” she shared with Medscape Medical News
Who Should Consider Taking Non-Hormonal Therapies?
During the perimenopause transition phase, as a woman’s estrogen and progesterone levels start to drop significantly, menopausal hormone therapy (MHT) is considered one of the fastest and most effective ways to treat the bothersome VSM that can occur since MHT works to replenish the body’s estrogen and progesterone levels.
Some women should not be administered MHT even if they are requesting it to be prescribed by their doctors. Menopausal women with a history of breast or endometrial cancer, especially hormone receptor-positive (HR+) cancers, should not take MHT because these types of cancer cells have receptors for estrogen, progesterone, or both, which can significantly increase the risk that these tumors can grow, metastasize and cause more serious complications. For this reason, women who have had breast or endometrial cancer, any family members who had these cancers, or those women who are considered high risk for developing these cancers should not be prescribed MHT. [7]
In addition, women with a history of venous thromboembolic events or stroke, gallbladder problems, and coronary heart diseases should avoid MHT. However, they can instead consider non-hormonal treatments like fezolinetant or elinzanetant.
How Effective Are Non-Hormonal Therapies For Treating VMS?
SKYLIGHT 1
SKYLIGHT 1, a Phase III randomized controlled clinical study, was performed to assess the effectiveness of fezolinetant in treating moderate-to-severe vasomotor symptoms associated with menopause. The clinical study included over 500 women between 40 and 65 years of age, who were selected from around the world and who had experienced at least seven hot flashes a day. [8]
The study participants were split into three groups, one receiving a placebo intervention and the other two receiving 35 mg and 45 mg of fezolinetant, respectively. After 4 weeks, the women who were administered fezolinetant reported a reduction in the frequency and severity of hot flashes. After 12 weeks, 45% of women taking 30 mg of fezolinetant, 57% of women taking 45 mg of fezolinetant, and 30% of the placebo group reported a reduction in the frequency of hot flashes. [8]
The study's authors also wrote that the participants reported better quality of life and fewer night-time awakenings. [8]
OASIS 1 and 2
Bayer conducted three Phase III clinical studies–OASIS 1, 2, and 3–to analyze the effectiveness of elinzanetant. OASIS 1 and 2 were specifically conducted to analyze the impact of elinzanetant on moderate to severe VMS, its effects on sleep disturbances, and overall menopause-related quality of life. These trials followed a double-blind, placebo-controlled design to ensure accurate results.
Both OASIS 1 and 2 studies met all primary endpoints. Compared to the placebo, there was a 50% reduction in the frequency and severity of hot flashes in 80% of participants taking elinzanetant by the fourth and twelfth weeks. In addition, the participants also said they slept better while taking elinzanetant. Improvement in these areas was seen as early as week one, indicating a rapid onset of action. The drug’s safety was consistent with prior studies, with no unexpected adverse effects.
According to Dr Michelle Jacobson, a Canadian OB/GYN physician and certified menopause specialist based in Toronto, Canada, these findings mark a significant milestone for managing menopausal symptoms. She said, “As a menopause specialist, I am truly excited to see the results of the Phase III trials on elinzanetant. For so long, we have been treating those suffering from menopausal symptoms with second-line, non-indicated therapies. Now, we are one step closer to having effective, indicated, and safe treatments for our patients. I look forward to being able to offer women a novel treatment that has such positive outcomes once it is approved by Health Canada. The more options we have, the better we can individualize therapies for our patients to help them live their best and healthiest lives possible."
Claudio N Soares, MD, PhD, who is a Professor of Psychiatry at Queen’s University in Canada, an experienced clinical researcher in menopause and women’s mental health, and President-elect of The Menopause Society, also expressed similar views.
“These results are really encouraging. For too long, we have underestimated, sometimes even overlooked, the negative impact that menopausal symptoms–hot flashes, sleep disturbances, mood changes–may have on a woman’s health and quality of life. It is reassuring to see that this is no longer the case and that women may soon have access to novel, non-hormonal options to alleviate these symptoms and improve their quality of life”.
While the findings of OASIS 3 have not yet been published, the study was performed with a large sample size of participants to confirm the findings of OASIS 1 and 2. [9][10]
Are There Any Side Effects?
In the SKYLIGHT 1 study, a significant number of participants had experienced side effects or adverse reactions (listed below), which were 37% of women taking 30 mg and 43% of women taking 45 mg Fezolinetant. Interestingly, 45% of women in the placebo group (who were not taking any drug) also reported similar side effects. So, the difference in side effects between the drug medication group and placebo groups was minimal. [8]
The most commonly reported side effects included:
-
Headache
-
Abdominal pain
-
Diarrhea
-
Insomnia
-
Back pain
-
Elevated hepatic transaminase levels (potential risk of liver damage)
The study also included a warning for potential liver damage or elevated hepatic transaminase levels. Therefore, women considering Fezolinetant are advised to have their baseline bloodwork done to evaluate liver function and injury before starting the medication. While on the drug, follow-up blood tests should be performed every three months for the first nine months of treatment to monitor liver health.
Additionally, patients should watch for symptoms and signs of liver damage, such as nausea, vomiting, or jaundice (yellowing of the skin and eyes), and contact their physician if these signs appear.
With elinzanetant, no participant showed signs of hepatotoxicity or possible drug-induced liver injury. Safety assessments were performed to look for adverse effects in participants and included endometrial biopsies, bone mineral density, weight, and blood tests. It was found that 30.4% of participants taking elinzanetant and 14.6% of participants taking the placebo pill reported adverse effects, which were, most commonly, headache, fatigue, and sleepiness. [9]
Final Thoughts
Over 75% of menopausal women experience VMS, with 25% describing their symptoms as severe. In one-third of women, these symptoms can persist for seven years or more.[11] A pooled analysis of individual-level data revealed that women experiencing both persistent and severe hot flashes and night sweats had a significantly higher risk of cardiovascular disease (CVD). [12]
In such cases, having access to medications like fezolinetant and elinzanetant will not only expand treatment options for women but also prove to be an effective alternative for women who should not take HRT.
It should be noted that both fezolinentant and elinzanetant are very new classes of drugs that do not have a long clinical history, and as such, the clinical practice guidelines on how to incorporate them into the treatment regimen are currently unclear. While both these drugs will prove to be exciting options for women, whether they can be used in combination with other treatments for menopausal symptoms still needs further study.
References:
[1] Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006 Jul;96(7):1226-35. doi: 10.2105/AJPH.2005.066936. Epub 2006 May 30. PMID: 16735636; PMCID: PMC1483882.
[3] https://www.bayer.com/en/us/news-stories/new-drug-application-to-us-fda-for-elinzanetant
[4] Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Mohideen P, Lin VH, Stern TP, Panay N, Hunter MS, Webber LC, Dhillo WS. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause. 2018 Aug;25(8):862-869. doi: 10.1097/GME.0000000000001090. PMID: 29533369; PMCID: PMC6092106.
[5] Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 Dec;27(12):1350-1356. doi: 10.1097/GME.0000000000001621. PMID: 32769757; PMCID: PMC7709922.
[6] Pawsey S, Mills EG, Ballantyne E, Donaldson K, Kerr M, Trower M, Dhillo WS. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234. doi: 10.1210/clinem/dgab108. PMID: 33624806; PMCID: PMC8277204.
[7] Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci. 2023 Apr 6;24(7):6834. doi: 10.3390/ijms24076834. PMID: 37047814; PMCID: PMC10095386.
[8] Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomized controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. PMID: 36924778.
[9] Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(16):1343–1354. doi:10.1001/jama.2024.14618
[12] Zhu, Dongshan et al.Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies; American Journal of Obstetrics & Gynecology, Volume 223, Issue 6, 898.e1 - 898.e16
Related Readings: PCOS
Coming soon
Coming soon
AI-based Prediction Models for Diagnosing PCOS
(Polycystic Ovary Syndrome)
Source: Journal of Medical Internet Research
August 22, 2023
An observational study explored how artificial intelligence and digital healthcare are improving the diagnosis of polycystic ovary syndrome (PCOS). The study used AI and digital tools to construct predictive models that can help physicians diagnose PCOS. These models achieved impressive accuracy rates (around 81-90%) and required patient data to give user-friendly information to patients and doctors, making it easier to proactively diagnose PCOS.
